Loading...
Docoh

PDS Biotechnology (PDSB)

News

From Benzinga Pro
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
11 May 22
Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recap: PDS Biotechnology Q1 Earnings
11 May 22
Earnings, News
PDS Biotechnology (NASDAQ:PDSB) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
PDS Biotechnology Q1 EPS $(0.32) Misses $(0.22) Estimate
11 May 22
Earnings, News
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 128.57 percent decrease over losses of $(0.14) per share
Earnings Scheduled For May 11, 2022
11 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
PDS Biotech Reports Received $1.2M Following Sale Of Its Net Operating Loss Tax Benefits Through New Jersey Economic Development Program
19 Apr 22
News, Asset Sales
PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the
What Were Your Best And Worst Stock Buys? What Does The Zinger Nation Think?
6 Apr 22
Penny Stocks, Psychology, Crowdsourcing, Top Stories, Exclusives, Personal Finance, Trading Ideas, General
Admitting to success is a lot easier than failure and when it comes to stocks, not only is there money involved, but also questioning your — or your advisor's — judgment. And then there is the advice you hear in a coffee shop. (More on that later.)
PDS Biotechnology: Q4 Earnings Insights
31 Mar 22
Earnings, News
PDS Biotechnology (NASDAQ:PDSB) reported its Q4 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
31 Mar 22
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For March 31, 2022
31 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
Earnings Outlook For PDS Biotechnology
30 Mar 22
Earnings
PDS Biotechnology (NASDAQ:PDSB) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that PDS Biotechnology will report an earnings per share (EPS) of $-0.24.
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
30 Mar 22
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA, Top Stories, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
27 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, Trading Ideas, General
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
PDS Biotechnology Earnings Conference Call Is Coming Up, Here's What You Need To Know
24 Mar 22
Earnings, News
PDS Biotechnology (NASDAQ:PDSB) will host a conference call at 08:00 AM ET on March 31, 2022, to discuss Q4 2021 earnings results.
Earnings Scheduled For March 23, 2022
23 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter.
Earnings Preview For PDS Biotechnology
22 Mar 22
Earnings
PDS Biotechnology (NASDAQ:PDSB) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate that PDS Biotechnology will report an earnings per share (EPS) of $-0.24.
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
20 Mar 22
Biotech, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.
PDS Biotech Announces Achievement Of An Enrollment Objective In National Cancer Institute-Led Phase 2 Clinical Trial Of PDS0101-Based Combination In Advanced HPV-Associated Cancers
15 Mar 22
Biotech, General
PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing molecularly-targeted cancer therapies and infectious disease vaccines based on the Company's proprietary
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
20 Feb 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

Press releases

From Benzinga Pro
PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results
11 May 22
Biotech, Earnings, Press Releases, General
FLORHAM PARK, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and
PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
27 Apr 22
Biotech, News, Health Care, Press Releases, General
Preliminary efficacy and safety update on PDS0101 in combination with KEYTRUDA® (pembrolizumab) in first-line recurrent or metastatic HPV-positive head and neck cancerPreliminary efficacy and safety update by NCI on
PDS Biotech Chief Medical Officer, Lauren V. Wood, to Chair Session at the World Vaccine Congress
20 Apr 22
Biotech, News, Health Care, Press Releases, General
FLORHAM PARK, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies
PDS Biotech Receives $1.2 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program
19 Apr 22
News, Contracts, Press Releases
FLORHAM PARK, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies
PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call
22 Mar 22
Biotech, News, Press Releases, General
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the
PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers
15 Mar 22
Biotech, Health Care, Press Releases, General
FLORHAM PARK, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing molecularly-targeted cancer therapies and infectious disease
PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium
24 Feb 22
Biotech, Health Care, Press Releases, General
Preliminary safety data has shown that PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe